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Objective: This study was performed to identify whether growth and differentiation factor-9 (GDF-9) and transforming growth factor-β1 (TGF- 
β1) expressions would be lower in the follicular fluid (FF) of those over age 35 who underwent IVF than under age 35.
Methods: A total of 24 IVF cycles (20 patients) were included in this study. All of patients were stimulated for IVF by the GnRH short protocol 
and divided into two groups for analysis, according to their age: <35 group (14 cycles, 11 patients) vs. ≥35 group (10 cycles, 9 patients). The 
expression levels of GDF-9 and TGF-β1 were determined by western blotting and quantitative enzyme-linked immunosorbent assay. 
Results: The numbers of retrieved oocytes and metaphase II oocytes were significantly lower in the ≥35 group. Lower expression of GDF-9 
and TGF-β1 by western blotting in the ≥35 group were observed as well. The mean GDF-9 and TGF-β1 levels by enzyme-linked immunosor-
bent assay were lower in the ≥35 group. The values were 6,850.5±928.4 ng/L vs. 3,333.3±1,089.2 ng/L of GDF-9 (p<0.05) and 3,844.1±571.1 
ng/L vs. 2,187.7±754.0 ng/L of TGF-β1 (p<0.05). A negative correlation between GDF-9 and age was observed (r=-0.546, p=0.006). 
Conclusion: GDF-9 and TGF-β1 production from stimulated ovaries during IVF appears to decrease with age.
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Introduction
It has been well known that female fecundity, the ability to produce 
offspring, decreases with increasing chronological age. Studies have 
shown a clear decline in fecundity after the age of 30 years, leading 
to fertility loss at a mean age of 41 years [1,2]. In assisted reproduc-
tive technology (ART), the success rate declines with age as well [3]. 
This fact suggests the important implication that the population in 
the country would be expected to decrease in the future, due to the 
recent tendency to postpone marriage and childbearing. Although 
there have been several markers for predicting ovarian response, few 
studies have shown age-related quantitative differences in growth 
and differentiation factor-9 (GDF-9) and transforming growth factor- 
β1 (TGF-β1) from the follicular fluid during IVF. 
GDF-9, one of the TGF-β superfamily, is secreted from oocytes dur-
ing folliculogenesis and it is essential for female fertility and folliculo-
genesis [4,5]. A GDF-9 deletion results in decreased granulosa cell 
proliferation, abnormal oocyte growth and follicle development fail-
ure [6]. GDF-9 prevents granulosa cell apoptosis and follicular atresia 
as well [7]. 
The TGF-β proteins are a member of peptide growth factors that 
play an important role in regulating growth, differentiation, and me-
tabolism of many mammalian cell types. They belong to a superfam-
ily of structurally related dimeric proteins including activins and in-
hibins, bone morphogenetic proteins, and Müllerian inhibiting sub-
stances [8,9]. In the human follicle, TGF-β1 and TGF-β2 have been 
found to be produced in both theca and granulosa cells in culture 
[10]. TGF-β1 might thus be involved in the regulation of follicular grow-
th and oocyte maturation.
Many studies about growth factors in follicular fluid (FF) from the 
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ovary have focused on their biologic role or molecular interactions 
between oocytes and stromal cells. To our knowledge, no study has 
been performed to produce the quantitative assay on GDF-9 and TGF- 
β1 from human FF stimulated for IVF according to age. This study aims 
to investigate whether GDF-9 and TGF-β1 secreted from oocytes or 
theca and granulosa cells are correlated with IVF patient age.
Methods 
1. Study subjects
Among cases of cryopreserved FF undergoing controlled ovarian 
hyperstimulation (COS) with GnRH agonist for IVF from January 2009 
to September 2011, patients aged 27-44 years, with a basal FSH con-
centration <10 mIU/mL, no poor ovarian response, and a body mass 
index of 15-27 kg/m
2 were included in this study. The FF samples with 
any of the following characteristics were excluded: massive blood 
contamination during collection, no oocyte contained in the FF, total 
oocyte number ≥15 or ≤3, endometriosis fluid contamination, poly-
cystic ovarian syndrome defined by the 2003 Rotterdam criteria, more 
than 3,000 IU gonadotropin injection per cycle and ICSI cycle. 
A total of 24 IVF cycles from 20 patients were included in this study. 
The cycles were divided into two subgroups: a <35 group and a ≥35 
group, calculated from the experimental date. This study was review-
ed by the institutional ethical board. 
2. COS 
Patients were stimulated with recombinant FSH (Follitrope; LG Life 
Sciences, Seoul, Korea) and hMG (IVF-M; LG Life Science) along with 
GnRH agonists, buserelin acetate (Suprefact; Sanofi-Aventis Deutsch-
land GmbH, Frankfurt am Main, Germany) according to the short 
protocol. Monitoring of follicular development by real-time ultra-
sound scans was performed from day 5 of gonadotropin injection 
until the day before follicular puncture. When at least one ovarian fol-
licle had rea ched 18 mm in diameter, 10,000 IU of HCG (IVF-C; LG Life 
Science) were administered 34-36 hours before follicular aspiration.
3. FF collection
FF was sampled by trans-vaginal ultrasound-guided puncture and 
aspiration of follicles with a diameter of at least 15 mm. Fluid from 
the aspiration tubes without massive blood contamination was care-
fully collected. The tubes without oocyte were discarded. FF samples 
were centrifuged at 1,300 g for 10 minutes and stored at -70°C prior 
to the experiment.
4. Western blot analyses for GDF-9 and TGFβ1
Western blot was initially used to identify the presence of relative 
expression differences between the <35 and ≥35 groups. Eighteen 
FF samples (9 samples from each group) were mixed with 5 X load-
ing buffer and were electrophoresed using 15% sodium dodecyl sul-
fate-polyacrylamide gel electrophoresis, and then transferred to a ni-
trocellulose membrane for 90 minutes at 90 V. The blots were blocked 
with 3% non-fat dry milk in tris-buffered saline, then incubated with 
primary antibody. The GDF-9 and TGF-β1 were assayed using anti 
GDF-9 (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA; GDF-9 [C-
20], sc-7407) and TGF-β1 (Santa Cruz Biotechnoloigy Inc.; TGF-β1 
[3C11], sc-130348) [11]. After washing, the blots were incubated with 
anti-goat horseradish peroxidase-conjugated secondary antibodies 
for 1 hour and washed again. Immunodetection was carried out us-
ing an enhanced chemiluminescence peroxidase substrate solution 
(Elpis Biotechnology, Daejeon, Korea).
5. Assay of GDF-9 and TGF-β1 level in follicular fluid
After identification of qualitative differences by western blot, the 
levels of GDF-9 and TGF-β1 were measured by the modification of an 
enzyme-linked immunosorbent assay (ELISA) to verify quantitative 
differences between the two groups. The samples of FF were diluted 
1:10 in assay buffer (NaCl 0.8%, Na2HPO4 0.142%, KH2PO4 0.02%, KCl 
0.02%, BSA 0.5%, Tween 20 0.01%, pH 7.4). The ELISA was performed 
by coating 96-well plates with antibody with specificity for GDF-9 or 
TGF-β1. After incubating 2 hours at room temperature, the plates 
were washed, and horseradish peroxydase-conjugated secondary 
antibody was added to each well. After a further 1 hour of incuba-
tion, the plates were washed completely, and 5´-tetramethylbenzi-
dine solution (Invitrogen, Carlsbad, CA, USA) was added to each well. 
Absorbance at 450 nm was read on a microplate reader (BIOTEKEL-
312e; BioTek Instruments, Winooski, VT, USA) [12]. 
6. Statistical analyses
Statistical analyses were performed with IBM SPSS Amos ver. 19 
(IBM, Armonk, New York, USA). Data were analyzed by the Mann-Whit-
ney U test, chi-square test, and Pearson correlation test. A p-value less 
than 0.05 was considered to be statistically significant. All results are 
given as mean±SD or SE. 
Results
1. Clinical features of the two groups
The mean ages were 32.6±1.6 (<35 group), and 37.3±1.5 (≥35 
group). The amount of basal FSH and injected gonadotropin were 
not shown to be significantly different. Total retrieved oocyte and 
metaphase II oocyte numbers were significantly lower in the ≥35 
group (p=0.011, 0.007). The fertilization rate and clinical pregnancy 
rate were not significantly different (Table 1).  http://dx.doi.org/10.5653/cerm.2011.38.4.210
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2. Western blot for GDF-9 and TGF-β1
All of the bands are shown in Figures 1A and 2A. The GDF-9 bands 
from each group were detected at 57 kDa. The TGF-β1 band was de-
tected at 25 kDa as well. Densitometric analyses for relative quantita-
tive differences between the two groups showed significantly lower 
levels in the ≥35 group in Figures 1B and 2B.
3. ELISA for GDF-9 and TGF-β1
A statistically significant difference in the GDF-9 level was observed: 
6,850.5±928.4 ng/L (<35 group) vs. 3,333.3±1,089.2 ng/L (≥35 
group) of GDF-9 (p=0.004). TGF-β1 also exhibited the significant dif-
ference between the two groups: 3,844.1±571.1 ng/L vs. 2,187.7± 
754.0 ng/L (Figure 3). All values are mean±SE.
4. Correlation analysis between growth factors and age
Both growth factors were correlated negatively with age. GDF-9 
Table 1. Comparisons of IVF outcomes from under 35 and over 35 
groups
Age (yr)  <35 ≥35 p-value
No. of cycles   14   10
No. of patients   11     9
Patients’ age 32.6±1.6 37.3±1.5 <0.001
a
Basal FSH (mIU/mL) 6.4±1.7 6.9±1.5 0.494
BMI (kg/m
2) 20.5±2.9 21.8±2.7 0.857
Amount of gonadotropins (IU) 2,078.6±773.4 2,190.0±580.8 0.716
Peak E2 level (pg/mL) 1,987.2±1,095.4 1,466.2±619.9 0.124
No. of oocytes retrieved 8.4±2.5 6.0±2.0 0.011
a
No. of MII oocytes 7.2±2.1 4.5±2.2 0.007
a
No. of fertilized oocytes 5.4±1.7 3.9±2.0 0.066
No. of embryo transferred  3.7±1.3 3.6±1.4 0.842
Clinical pregnancy rate (%) 3/14 (21.4) 2/10 (20.0) 0.932
Values are presented as number (%) or mean±SD. 
BMI, body mass index; MII, metaphase II.
ap<0.05.
Figure 1. Western blot of relative growth and differentiation factor-9 (GDF-9) expression in follicular fluid. (A) Detection of protein with an ap-
proximate molecular weight of 57 kDa from follicular fluid using anti-GDF-9 antibodies. The upper bands are the <35 age group. (B) Numerical 
values of 18 cases were obtained by densitometric scanning. Values demonstrating the difference between the <35 and ≥35 groups were sta-
tistically significant (p<0.001). 
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Figure 2. Western blot of relative transforming growth factor-β1 (TGF-β1) expression in follicular fluid. (A) Detection of protein with approxi-
mate molecular weight of 25 kDa in follicular fluid using anti-TGF-β1 antibodies. The upper bands are the <35 age group. (B) Numerical values 
of 18 cases were obtained by densitometric scanning. Values demonstrating the difference between the <35 and ≥35 groups were statistical-
ly significant (p<0.001). 
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Figure 4. Pearson correlation analysis of growth and differentiation factor-9 (GDF-9) and transforming growth factor-β1 (TGF-β1) between ages 
and values. 
ap<0.05. 
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showed a stronger negative correlation (r=-0.546) than that of TGF- 
β1 (r=-0.376). However, a statistical significance was found only in 
GDF-9 (p=0.07) (Figure 4).
Discussion
The proportion of infertile couples (failure to achieve a pregnancy 
within 1 year) reaches 10-20% in women over age 35, in contrast to 
only 4% for women in their twenties. Moreover, infertility rates may 
rise to 30-50% for only moderately fecund women of age 35 and 
over who have tried to conceive for several years [13]. Age-related in-
fertility is usually considered a problem that can be easily solved by 
assisted reproductive technology. However, the molecular features of 
the aspirated FF of aged women are not yet known. Many studies on 
growth factors of FF are concentrated on the production mechanisms 
or their interactions with each other by using animal models. There-
fore, it is meaningful to evaluate whether the expression differences 
of various growth factors secreted from the ovary exist in humans ac-
cording to patient age. In the present study, age 35 was chosen as 
the age for dividing the group into two subgroups. 
Recently, GDF-9 has aroused a great deal of interest as a specific 
oocyte-secreted molecule. It has been thought for a long time that 
the oocyte is passive in terms of its relationship with follicular somat-
ic cells. However, it has recently become evident that the oocyte in 
fact is a central regulator of follicular cell function and thereby plays a 
critical role in the regulation of oogenesis, ovulation rate, and fecun-
dity [14]. GDF-9 is involved in early folliculogenesis, regulation of gra-
nulosa cell differentiation, and ovarian function pathogenesis [15]. 
However, much of its cellular biology remains poorly understood. In 
the present study, we found that the GDF-9 concentration was signif-
icantly lower in the ≥35 group. This might be related to the lower to-
tal numbers of oocytes and metaphase II oocytes. However, the preg-
nancy rate did not differ between the two groups in this study. That 
is attributed to the small number of cases included. 
TGF-β1, one of the TGF-β isoforms (among TGF-β1, TGF-β2, and 
TGF-β3), an mRNA/protein in the preantral follicles, has been found 
in several organisms including rodents, humans, sheep, and cattle 
[16,17]. However, the precise cellular distribution varied according to 
the species studied, the follicular stage, and most likely, the detection 
method used. In humans, TGF-β is produced by both theca and gran-
ulosa cells, while in sheep, cows, and pigs it is produced mainly in 
theca cells [18]. In this study, TGF-β1 was chosen as a marker secreted 
from the theca and granulosa cells, which might reflect ovarian activ-
ity. Then, we hypothesized that the TGF-β1 secretion would be influ-
enced by aging. As we had expected, lower expression in the older 
group was observed. 
Previous studies have used individual samples of FF in order to cor-
relate FF substances with oocyte quality and oocyte nuclear maturity 
assessed by ICSI. However, FF was been collected as a whole without 
Figure 3. Comparisons of growth and differentiation factor-9 (GDF-9) 
and transforming growth factor-β1 (TGF-β1) analyzed by enzyme-
linked immunosorbent assay. GDF-9 and TGF-ß1 levels in the ≥35 
group were significantly lower.
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follicle individualization in this study. According to a recent study on 
GDF-9 and bone morphogenetic protein-15, oocyte and embryo qual-
ity are affected by those growth factors [19]. Despite the differing FF 
collection protocol, we were able to find lower numbers of total oo-
cytes and metaphase II oocytes among the ≥35 group with lower 
GDF-9 and TGF-β1 levels as well (Table 1). However, other studies us-
ing other growth factors, such as inhibin and insulin-like growth fac-
tor, showed less consistent results [20,21]. Therefore, more study is 
needed to verify the growth factor effect on oocyte and embryo quality.
Although it is common to present the control band in western blot 
experiments, a control band was not presented in this study because 
there was no well-known protein marker considered as the standard 
for FF.
Reproductive aging has been the current focus of attention for re-
productive medicine. It has been clearly demonstrated that women 
in their late 30s and early 40s are distinctly less fertile and less likely 
to conceive than younger women [22]. Recently, raising the infertility 
rate among older women became a public concern because the low 
birthrate distorts the population and weaken the country’s industry. 
In recent decades, ART treatment has confirmed that the probability 
of a live birth decreases distinctly after the age of 35 years. However, 
few of the molecular characteristics of the aging ovary are known. 
Studies on the follicular features of the aging ovary are much needed. 
In conclusion, lower expression of GDF-9 and TGF-β1 were found in 
the FF of older women who underwent IVF. This would suggest that 
the aging ovary has some dysfunction in producing growth factors 
for follicle development and produces oocytes with poor quality.
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